This paper examines arguments in favor and against the of patent rights on pharmaceuticals in the developing world as required by World Trade Organization membership. It emphasizes that these new pharmaceutical patents promise benefits and costs that differ with the characteristics of diseases. It also considers standard intellectual property and regulatory mechanisms that could be used to differentiate protection, and concludes that all have serious drawbacks. It then describes a new mechanism that would make differentiating protection a more feasible policy option.
Over the last several years, the United States and other major donor countries have supported a historic initiative to write down the official debts of a group of heavily indebted poor countries, or HIPCs. Donor countries had two primary goals in supporting debt relief: to reduce countries' debt burdens to levels that would allow them to achieve sustainable growth; and to promote a new way of assisting poor countries focused on home-grown poverty alleviation and human development. While the current "enhanced HIPC" program of debt relief is more ambitious than any previous initiative, it will fall short of meeting these goals. We propose expanding the HIPC program to include all low-income countries and increasing the resources dedicated to debt relief. Because debt relief will still only be a first step, we also recommend reforms of the current "aid architecture" that will make debt more predictably sustainable, make aid more efficient, and help recipient countries graduate from aid dependence.